2024
Accelerated Bacille Calmette-Guérin reactions: More than meets the eye
Villanueva P, Crawford N, Croda M, Croda J, Dalcolmo M, Jardim B, de Almeida Pinto Jardim T, Marshall H, Prat-Aymerich C, Sawka A, Sharma K, Troeman D, Warris A, Wood N, Messina N, Pittet L, Curtis N. Accelerated Bacille Calmette-Guérin reactions: More than meets the eye. Heliyon 2024, 10: e32510. PMID: 39027494, PMCID: PMC11255489, DOI: 10.1016/j.heliyon.2024.e32510.Peer-Reviewed Original ResearchInterferon-gamma release assayBacille Calmette-GuerinTB prevalence settingInjection site reactionsBCG reactionBCG vaccinationSite reactionsTB infectionLow TB prevalence countriesHistory of BCG vaccinationLocal injection site reactionsBacille Calmette-Guerin vaccineTB prevalence countriesInternational randomised trialLatent TB infectionDays of vaccinationSafety surveillance dataActive tuberculosisAdverse eventsBCG vaccineesMycobacterial exposureRelease assayClinical significanceTB symptomsFemale sexFactors influencing adverse events following COVID-19 vaccination
Villanueva P, McDonald E, Croda J, Croda M, Dalcolmo M, dos Santos G, Jardim B, Lacerda M, Lynn D, Marshall H, Oliveira R, Rocha J, Sawka A, Val F, Pittet L, Messina N, Curtis N. Factors influencing adverse events following COVID-19 vaccination. Human Vaccines & Immunotherapeutics 2024, 20: 2323853. PMID: 38445666, PMCID: PMC10936640, DOI: 10.1080/21645515.2024.2323853.Peer-Reviewed Original ResearchConceptsVaccine typesSystemic reactionsIncidence of AEFIAdverse eventsVaccine doseIncidence of adverse eventsCovid-19 specific vaccineCOVID-19 vaccineNested cohort studyIgG antibody responsesRisk of AEFICOVID-19 vaccine typesChAdOx1 recipientsBNT162b2 recipientsCohort studyPfizer-BioNTechCoronaVac vaccineAntibody responseChAdOx1Oxford-AstraZenecaCoronaVacBNT162b2Local reactionsDoseDevelopment of COVID-19 vaccines
2023
Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API)
Barbosa A, Chebabo A, Starling C, Pérez C, Cunha C, de Luna D, Nunes E, Zambrano G, Ferreira J, Croda J, Falavigna M, Gomes-da-Silva M, Thormann M, Cimerman S, Parahiba S, Tanni S, Bernardo W, Rodriguez-Morales A. Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API). Annals Of Clinical Microbiology And Antimicrobials 2023, 22: 67. PMID: 37550690, PMCID: PMC10408214, DOI: 10.1186/s12941-023-00623-w.Peer-Reviewed Original ResearchConceptsUse of hydroxychloroquineInfectious diseasesCOVID-19Treatment of outpatientsSARS-CoV-2/COVIDSevere COVID-19Evidence-based guidelinesPan American AssociationGuideline development processLack of benefitEvidence-based medicineAdverse eventsMechanical ventilationClinical manifestationsTherapeutic optionsPharmacological treatmentCOVID-19 episodeInpatient settingAmerican guidelinesGRADE systemSystematic reviewStrong recommendationsProphylaxisOutpatientsDisease